ES2941629T3 - Ligandos del receptor de neurotensina - Google Patents
Ligandos del receptor de neurotensina Download PDFInfo
- Publication number
- ES2941629T3 ES2941629T3 ES20166422T ES20166422T ES2941629T3 ES 2941629 T3 ES2941629 T3 ES 2941629T3 ES 20166422 T ES20166422 T ES 20166422T ES 20166422 T ES20166422 T ES 20166422T ES 2941629 T3 ES2941629 T3 ES 2941629T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- group
- acceptor
- effector
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2941629T3 true ES2941629T3 (es) | 2023-05-24 |
Family
ID=47355771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20166422T Active ES2941629T3 (es) | 2012-12-07 | 2013-12-06 | Ligandos del receptor de neurotensina |
| ES13814827T Active ES2795923T3 (es) | 2012-12-07 | 2013-12-06 | Ligandos de receptores de neurotensina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13814827T Active ES2795923T3 (es) | 2012-12-07 | 2013-12-06 | Ligandos de receptores de neurotensina |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10961199B2 (enExample) |
| EP (3) | EP2740726A1 (enExample) |
| JP (2) | JP6576828B2 (enExample) |
| KR (1) | KR102290803B1 (enExample) |
| CN (2) | CN109320502B (enExample) |
| AU (1) | AU2013354422B2 (enExample) |
| BR (1) | BR112015012530B1 (enExample) |
| CA (1) | CA2893605C (enExample) |
| DK (2) | DK3712131T3 (enExample) |
| ES (2) | ES2941629T3 (enExample) |
| FI (1) | FI3712131T3 (enExample) |
| HU (2) | HUE050388T2 (enExample) |
| IL (1) | IL239080B (enExample) |
| MX (1) | MX370354B (enExample) |
| PL (2) | PL3712131T3 (enExample) |
| PT (2) | PT3712131T (enExample) |
| RU (1) | RU2671970C2 (enExample) |
| SG (2) | SG10201704564QA (enExample) |
| WO (1) | WO2014086499A1 (enExample) |
| ZA (1) | ZA201503446B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015273934B2 (en) * | 2014-06-10 | 2020-08-20 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| CN108473541B (zh) * | 2015-11-24 | 2023-05-12 | 特拉斯福特普拉斯公司 | 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 |
| EP3279197A1 (en) * | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| IL324632A (en) | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| MY197688A (en) | 2017-07-24 | 2023-07-05 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| WO2021005125A1 (en) * | 2019-07-08 | 2021-01-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| MX2023004715A (es) * | 2020-10-22 | 2023-05-10 | Nihon Mediphysics Co Ltd | Metodo para producir un complejo de circonio radioactivo. |
| IL307632A (en) * | 2021-04-23 | 2023-12-01 | Fusion Pharmaceuticals Inc | Cancer treatment methods |
| CA3220010A1 (en) * | 2021-05-13 | 2022-11-17 | The General Hospital Corporation | Molecular probes for in vivo detection of aldehydes |
| EP4355377A4 (en) * | 2021-06-16 | 2025-05-07 | Fusion Pharmaceuticals Inc. | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL |
| WO2022261770A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| WO2022266357A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napox |
| CA3249925A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| IL314786A (en) * | 2022-02-18 | 2024-10-01 | Full Life Tech Hk Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| WO2023215778A1 (en) * | 2022-05-03 | 2023-11-09 | The University Of North Carolina At Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
| WO2025144920A1 (en) * | 2023-12-28 | 2025-07-03 | Radionetics Oncology, Inc. | Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| CA2183421A1 (en) | 1994-02-18 | 1995-08-24 | John Mertens | Labelled peptide compounds |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| WO1997004311A2 (en) | 1995-07-20 | 1997-02-06 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| DE69819478T2 (de) | 1997-02-03 | 2004-09-02 | Mallinckrodt, Inc. | Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| WO2000078796A2 (en) | 1999-06-24 | 2000-12-28 | Mallinckrodt Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| WO2005016141A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| CA2676413A1 (en) * | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| EP2334642B1 (en) * | 2008-09-16 | 2014-01-01 | The Regents Of The University Of California | Simplified one-pot synthesis of [18f]sfb for radiolabeling |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| US8586043B2 (en) * | 2009-01-07 | 2013-11-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1 |
| EP2454272B1 (en) | 2009-07-16 | 2017-08-23 | IASON GmbH | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en not_active Ceased
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en not_active Abandoned
-
2025
- 2025-05-29 US US19/222,493 patent/US20260078095A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2795923T3 (es) | Ligandos de receptores de neurotensina | |
| BR112015006453B1 (pt) | Antagonista de grpr radiomarcado e composição terapêutica que o compreende | |
| US20210402016A1 (en) | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders | |
| Alshoukr et al. | Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors | |
| JP2024542966A (ja) | 胃抑制ペプチドレセプターリガンド | |
| HK40037865A (en) | Neurotensin receptor ligands | |
| HK40037865B (en) | Neurotensin receptor ligands | |
| Zoghi et al. | Preclinical evaluation of new GnRH‐I receptor radionuclide therapy with 177Lu‐peptide tracer | |
| EP4455159A1 (en) | Gastric inhibitory peptide receptor ligands with bio-distribution modifier | |
| HK40003630A (en) | Neurotensin receptor ligands | |
| HK40003630B (en) | Neurotensin receptor ligands | |
| WO2021080409A1 (es) | (lys3)bn-ipsma radiomarcada para el reconocimiento dual de las proteinas psma y grpr in vivo | |
| HK1210148B (en) | Neurotensin receptor ligands |